Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

4 Best 5G Stocks to Buy as the Trend Heats Up

By Chris Lau, InvestorPlace Contributor

These five 5G stocks should benefit the most as 5G gets its start in 2019. Here's what you should know about each.

Why the Outlook of Square Stock Is Still Bright

By Chris Lau, InvestorPlace Contributor

SQ is partnering up with Postmates which should lead to higher growth, raising SQ stock and pleasing the owners of Square stock.

Why Investors Should Buy Nvidia Stock After Its Dip

By Chris Lau, InvestorPlace Contributor

A weak outlook from Intel hurt NVDA stock. This should not have happened because NVDA's prospects look bright.

5 Growthy Biotech Stocks to Buy Despite the Scrutiny

By Chris Lau, InvestorPlace Contributor

Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?

Why Nio Stock Could Be Worth Its Risk

By Chris Lau, InvestorPlace Contributor

Nio stock lost investors' trust when NIO reported weak Q4 results and issued a warning for the first AND second quarters.

Load More